ROS1 and non-small cell lung carcinoma: Repotrectinib is a novel-generation multitargeted tyrosine kinase inhibitor (TKI), with data available for ROS1-positive Non-Small Cell Lung Cancer (NSCLC) through the ongoing TRIDENT-1 trial.